GH Secretagogues
IGF-1 LR3
← Back to Library
Limited / unverified Limited / unverified Limited / unverified GH Axis Repair
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 1 mg
Dosing window: Post-Workout
Receptor / target: IGF-1
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 33mcg daily | 1x/day, 7 days per week. Dose immediately post-workout (within 30 mins) with carbs and protein. |
| Week 2 | 50mcg daily | 1x/day, 7 days per week. Avoid taking at bedtime or while fasted. |
| Weeks 3-4 | 75mcg daily | 1x/day, 7 days per week. Ensure adequate calories/protein are consumed. |
| Weeks 5-8 | 100mcg daily | 1x/day, 7 days per week. Maximum recommended dosage phase. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative: Bilateral IM
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 50mcg split (25mcg per side) | Administered intramuscularly into the trained muscle group (e.g., left and right bicep) immediately post-workout. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: GH-axis protocols are not 'more is better.' The logic is pulse quality, recovery time, IGF-1/glucose monitoring, and avoiding receptor desensitization, edema, appetite spikes, numbness, or blood-pressure strain. Entry context: target (IGF-1); route Subcutaneous; timing Post-Workout. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active cancer: IGF-1 is a potent mitogen; direct IGF-1 receptor activation accelerates proliferation of malignant cells. Limited / unverified
- History of malignancy: especially hormone-sensitive cancers; IGF-1 receptor signaling drives tumor growth in breast, prostate, and colorectal cancers. Limited / unverified
- Hypoglycemia or hypoglycemia unawareness: acute hypoglycemia is the primary risk; IGF-1 receptor activity mimics insulin; never administer fasted. Limited / unverified
- Diabetic ketoacidosis. Limited / unverified
- Type 1 or insulin-dependent diabetes: IGF-1's insulin-like activity requires careful glycemic management. Limited / unverified
- Concurrent use with insulin: severe additive hypoglycemia risk; extreme caution required. Limited / unverified
- Concurrent administration without food: administration without concurrent carbohydrates and protein is contraindicated; hypoglycemia risk is immediate. Limited / unverified
- Pre-existing visceral organ enlargement: IGF-1 at high doses drives growth in all IGF-1 receptor-expressing tissues, including intestinal epithelium and visceral organs. Limited / unverified
- Active acromegaly: additive IGF-1 receptor stimulation in a state of existing IGF-1 excess. Limited / unverified
- Pregnancy: IGF-1 analog activity not established in pregnancy; potential fetal risk. Limited / unverified
- Breastfeeding: safety not established. Limited / unverified
- Known hypersensitivity to IGF-1 LR3 or excipients. Limited / unverified
- Pediatric use: safety and efficacy not established; open growth plates in children risk inappropriate and disproportionate skeletal growth. Limited / unverified
Side effects (limited evidence)
- Severe hypoglycemia: the most critical adverse effect; direct insulin-like glucose uptake via IGF-1 receptor activation; onset typically 30-60 minutes post-injection; more pronounced with fasted administration; always administer with carbohydrates present. Limited / unverified
- Intestinal growth and gut hypertrophy: with abused long-term or excessive dosing, IGF-1 receptor stimulation in gastrointestinal epithelium can cause measurable organ enlargement; this is the primary long-term misuse risk. Limited / unverified
- Visceral organ growth: liver, spleen, kidneys; IGF-1 receptor is expressed in all visceral organs; supraphysiologic IGF-1 exposure over extended periods may drive size increases. Limited / unverified
- Localized swelling at injection site: tissue response to subcutaneous or intramuscular injection. Limited / unverified
- Edema: IGF-1-mediated sodium and fluid retention. Limited / unverified
- Jaw tightening or facial growth (at high doses/extended abuse): IGF-1 receptors in craniofacial tissues; acromegalic-type effects at very high doses. Limited / unverified
- Joint pain: GH/IGF-1 axis-mediated periarticular fluid. Limited / unverified
- Headache. Limited / unverified
- Fatigue: transient post-injection. Limited / unverified
- Nausea: dose-dependent. Limited / unverified
- Increased appetite: orexigenic effect of IGF-1 receptor activity. Limited / unverified
- Tingling or numbness in extremities: insulin-like effects and fluid shifts. Limited / unverified
- Carpal tunnel syndrome risk: with extended high-dose use. Limited / unverified
- Downregulation of endogenous GH production: negative feedback from elevated IGF-1 on hypothalamic-pituitary axis; natural GH production suppressed during and after long cycles. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.